Eudragit EPO nanoparticles: application in improving therapeutic efficacy and reducing ulcerogenicity of meloxicam on oral administration.

Khachane P, Date AA, Nagarsenker MS. Eudragit EPO nanoparticles: application in improving therapeutic efficacy and reducing ulcerogenicity of meloxicam on oral administration. J Biomed Nanotechnol. 2011 Aug; 7(4):590-7.

View in: PubMed

subject areas

Administration, Oral
Animals
Anti-Inflammatory Agents, Non-Steroidal
Male
Microscopy, Electron, Transmission
Nanocapsules
Nanotechnology
Particle Size
Polymethacrylic Acids
Rats
Rats, Sprague-Dawley
Solubility
Stomach Ulcer
Thiazines
Thiazoles

authors with profiles

Abhijit Date, PhD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support